FOLLOWING THE grant of Emergency Use Authorization (EUA) to Covid-19 treatment drug Ronapreve, the Department of Health (DOH) said it will need a recommendation from the Health Technology Assessment Council (HTAC) and Living CPG (Clinical Practice Guidelines) before the government procures the medicine.
The
DOH said that it has been reviewing the use of Ronapreve together with experts
who are continuously updating the Living CPG with regard to its use in the
clinical management of Covid-19 patients. Moreover, the health technology
assessment has to be concluded before hospitals can place an order through the
government.
It
said Ronapreve cannot be sold in the market since the government is the only
one allowed to procure and distribute it.
“Para
sa Ronapreve na may EUA, makaka-order po ang mga ospital kung may
approval na ng DOH. Bago po pahintulutan ng gobyerno na mag-place ng order ang
mga ospital ng Ronapreve ay dapat may rekomendasyon ito ng ating mga eksperto
mula sa HTAC at Living CPG,” said DOH Undersecretary Maria Rosario Vergeire.
Ronapreve
is a monoclonal antibody drug to prevent and fight Covid-19. The Food and Drug
Administration released the EUA for the drug on October 1 and is authorized for
confirmed mild to moderate Covid-19 patients aged 12 and above with a minimum
weight of 40 kilos and who do not need supplemental oxygen and are at high risk
of progressing to severe cases. (Zamboanga Post)
No comments:
Post a Comment